Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 18/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273959 | 0.89 | ROCK1 (0.44) | TSHR | |
| SCHEMBL3274899 | 0.87 | TSHR (0.42) | TSHRKDR | |
| SCHEMBL3273280 | 0.86 | TSHR (0.56) | PDE2ATSHR | |
| SCHEMBL3278158 | 0.83 | TSHR (0.43) | PDE2ATSHR | |
| SCHEMBL3273618 | 0.82 | ROCK1 (0.45) | PDE2ATSHR | |
| SCHEMBL3273980 | 0.82 | GSK3B (0.41) | PDE2AKDRTEK | |
| SCHEMBL3277952 | 0.82 | KCNMA1 (0.46) | TSHR | |
| SCHEMBL3277945 | 0.82 | KMT2A (0.47) | PDE2ATSHR | |
| SCHEMBL3274977 | 0.82 | TSHR (0.42) | PDE2ATSHR | |
| SCHEMBL3274514 | 0.81 | PDE2A (0.43) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592436-B2 | Arylamide pyrimidone derivatives | SANOFI (FR) | 2013-11-26 | — | — | US | claimed |
| EP-2148866-B1 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-17 | — | — | EP | claimed |
| US-20100087460-A1 | ARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | claimed |
| EP-1992620-A1 | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| US-8592436-B2 | Arylamide pyrimidone derivatives | SANOFI (FR) | 2013-11-26 | — | — | US | disclosed |
| EP-2148866-B1 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-17 | — | — | EP | disclosed |
| US-20100087460-A1 | ARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| EP-2148880-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008140947-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1992620-A1 | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087460-A1 | ARYLAMIDE PYRIMIDONE DERIVATIVES | DHFR, XDH, HPRT1 | PDE2A 1803/4885TSHR 479/4885KDR 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.